| Autor: | Robert Jordan, Patricia M. Sassoli, Tam Susan H, Dean J. Kereiakes, Mark A. Nedelman, Marian T. Nakada |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Hematology business.industry medicine.medical_treatment Percutaneous coronary intervention Tirofiban Pharmacokinetics Internal medicine Pharmacodynamics Anesthesia Conventional PCI Abciximab Eptifibatide Medicine Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of Thrombosis and Thrombolysis. 14:15-24 |
| ISSN: | 0929-5305 |
| Popis: | Background: Tirofiban and eptifibatide are currently approved for the medical stabilization of non-ST segment elevation acute coronary syndromes. In patients undergoing percutaneous coronary intervention (PCI) during infusion of these drugs, conversion to abciximab, which has long term proven clinical efficacy and cost-effectiveness, following PCI may be desirable. The purpose of this study was to determine if the binding or pharmacodynamics of abciximab is affected by a prior infusion of either tirofiban or eptifibatide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink